Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Synovial Sarcoma

  • Diederik de Bruijn
  • Ad Geurts van Kessel
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_5627-2


Human synovial sarcomas are soft tissue tumors that account for up to 10 % of all human sarcomas and mainly affect children and young adults. These tumors display relatively high rates of local recurrences and metastases (metastasis) and are therefore regarded as high grade tumors. Five- and ten-year survival rates of 60–80 % and 40–50 %, respectively, have been reported in several large retrospective studies. The tumors occur most frequently in the extremities (often associated with the large joints), but may also be encountered in a wide variety of organs. The name synovial sarcomas is misleading since it has become clear that they do not originate from synovial tissue. Instead, synovial sarcomas are thought to be derived from progenitor cells that are capable of differentiating into mesenchymal and/or epithelial structures. A very recent study indicated that these progenitor cells may, in fact, be primary myocytes. Histopathologically, synovial sarcomas can be subdivided...


Synovial Sarcoma Transcriptional Regulatory Activity Synovial Sarcoma Cell Transcription Regulatory Activity Specific Chromosomal Translocation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. de Bruijn DRH, Nap JP, van Geurts Kessel A (2007) The (epi)genetics of human synovial sarcoma. Genes Chromosomes Cancer 46:107–117CrossRefPubMedGoogle Scholar
  2. Guillou L, Benhattar J, Bonichon F et al (2004) Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 22:4040–4050CrossRefPubMedGoogle Scholar
  3. Haldar M, Hancock JD, Coffin CM et al (2007) A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 11:375–388CrossRefPubMedGoogle Scholar
  4. Ito T, Ouchida M, Morimoto Y et al (2005) Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 224:311–319CrossRefPubMedGoogle Scholar
  5. Raney RB (2005) Synovial sarcoma in young people: background, prognostic factors, and therapeutic questions. J Pediatr Hematol Oncol 27:207–211CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Human GeneticsRadboud University Nijmegen Medical CentreNijmegenThe Netherlands